Blood cancer gene therapies enter the clinic
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Nuvalent’s next battleground is HER2
NVL-330 features among the latest crop of industry projects newly into human trials.
Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
